Pharmaceuticals

Phase 3 Data Demonstrate Efficacy of Lenacapavir for HIV Prevention in Cisgender Women

bexib
By bexib 0 Min Read

Results from the PURPOSE 1 trial showed that treatment with lenacapavir was superior to treatment with Descovy and Truvada.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Bitcoin is the cash of the internet
Next Article Remy Cointreau is too focused on Cognac, say investors Reuters – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Plan ahead: Survive the CUPW strike
International Shipping
Creating and maintaining classroom maker spaces with Kristin Berbawy
Manufacturing
From Porsche to Purpose: A CMO’s Journey
Retail & E-commerce
Upskilling: An interview with Steph Piper
Manufacturing